The study will look at patients with spontaneous intracranial hemorrhage while taking statins. The patient will then be randomized to continue or discontinue statin therapy to continue to treat the patient after the initial event.

The purpose of this study is to better identify and predict individuals at risk for Alzheimer's disease (AD) who are most likely to benefit from personalized, evidence-based interventions. Studies have shown that endocrine aging (menopause, perimenopause) increases Alzheimer’s disease risk specifically in women. Our goal is to unravel the biological mechanisms behind the increased risk by analyzing how various measures of brain function, biochemistry, laboratory values, and other risk factors may influence Alzheimer’s risk as women age.

Parkinson's disease (PD) is heritable and due to specific mutations in a minority of patients. However, identifying such mutations is becoming increasingly important, as there are now clinical trials either ongoing or planned that are testing new therapeutics specifically targeting genetic forms of PD, and knowledge of their genetic status will provide such patients with the opportunity to consider whether they wish to participate in such trials.

The purpose of this study is to test whether active tasks completed on a personal smartphone are feasible as an approach to collecting data from patients with movement disorders. In particular, we are investigating whether it is a user-friendly interface for patients with movement disorders. The active tasks that participants will complete measure dexterity and speed, which are major components of the Unified Parkinson’s Disease Rating Scale and Movement Disorder Society Scales.

The purpose of this study is to learn about the character and course of rapid eye movement (REM) sleep behavior disorder (RBD) and REM sleep without atonia (RSWA).

In this study we hope to monitor you over a period of three years to observe any long-term changes in your clinical symptoms and to determine if they indicate the development of a neurodegenerative disorder, such as Parkinson’s disease.

The purpose of this double-blinded study is to find out about the ability of K0706, the study drug, to slow the progression of Parkinson's disease, as well as the safety of K0706. K0706 is intended to work by blocking a substance in the body called "Abl". Abl is a kind of Tyrosine Kinase Inhibitor. There is evidence from animal models that overactivation of Abl may play a role in Parkinson's disease, and that reducing this activity may help slow the progression of disease.

There are currently no medications proven to slow progression of Parkinson's disease.

Effective treatment to prevent disability MS has been largely non-existent due to a poor understanding of the relevant pathophysiologic mechanisms. The purpose of the study is use novel PET and MRI techniques to study acute multiple sclerosis (MS) lesion. We will use a Magnetic Resonance Imaging (MRI) imaging sequence (programmed set of parameters and magnetic gradients) which will measure myelin and iron within lesions. Positron Emission Tomography (PET) is another test which may be more detailed information about factors causing damage within MS lesions. MRI is a test approved by FDA.

This study aims to determine if apixaban is superior to aspirin for prevention of stroke or hemorrhage or death in patients with recent intracerebral hemorrhage or atrial fibrillation.

Parkinson's disease affects 1 in 100 people over the age of 65, but the time between Parkinson's disease onset and diagnosis can be many months or years. Interestingly, pathological hallmarks of Parkinson's in the brain can also be seen in the neurons in the gut and symptoms like constipation often precede the onset of tremor and incoordination by many years. It is now believed that Parkinson's disease may begin in the gut, at least in some people.

The study is investigating a link between high-risk plaque and cardioembolic sources among patients with stroke of unknown causes. This observational study uses an MRI protocol to detect bleeds within plaque, a marker of high-risk plaque. There is an additional PET/MRI that patients can opt into to more closely observe the plaque within the carotid arteries.

This study includes optional parts which will have financial compensation.